Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of CB06-036 in Healthy Chinese Subjects
NCT06101316Phase 1Recruiting
- Sponsor
- Zhimeng Biopharma
- Start
- Sep 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cb06-036 in Chronic Hepatitis B (CHB), sponsored by Zhimeng Biopharma. Primary endpoints: Abnormalities of vital signs at Day 3, Abnormalities of physical examination at Day 3 and 10 more. Started Sep 2023; status: recruiting.
02
Drugs
cb06-036
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06101316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06101316.